Lung Transplantation Clinical Trial
Official title:
Postconditioning by Cyclosporin A in Pulmonary Transplantation
The morbidity and mortality of patients undergoing lung transplantation in the acute phase
following surgical intervention is mainly due to the primary graft failure (PGF).
The occurrence of PGF is multi factorial but is mainly caused by ischemia-reperfusion injury.
The pulmonary graft suffers two periods of ischemia one when it is explanted from the donor
(cold ischemia) followed by another when it is grafted into the recipient's thoracic cavity
(warm ischemia). The brutal reperfusion of the graft exposes it to reperfusion injury that
causes PGF. PGF occurs in up to 20% of transplanted patients and is associated with
significantly higher levels of 30-days all-cause mortality. Patients with PGF have a 40%
mortality at 30-days versus a 6% mortality in patients without PGF.
Ischemic postconditioning, has recently been described in experimental models of
ischemia-reperfusion injury in the heart, and although not yet fully understood. Several
studies suggest that the mitochondria play a central role in cellular survival mechanisms
after a prolonged period of ischemia-reperfusion (with the mitochondrial permeability
transition pore (mPTP)).
Experimental studies have shown that cyclosporin A (CsA) administered prior to reperfusion
binds to cyclophilin D and blocks the opening of mPTP after reperfusion. This protective
effect of ischemia-reperfusion injury by CsA has been shown in experimental studies and in
clinical phase II trials in reperfused myocardial infarction patients.
The hypothesis of this study is that the administration of CsA in transplanted patients
(before re-opening of the first pulmonary graft vessels) protects the transplanted lung(s)
from the deleterious effects of ischemia-reperfusion injury and thus reduce the frequency and
severity of PGF.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02581111 -
Naloxone for Optimizing Hypoxemia Of Lung Donors
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02177916 -
Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation
|
N/A | |
| Not yet recruiting |
NCT01394835 -
Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients
|
Phase 2 | |
| Completed |
NCT01204970 -
Confocal Laser Micro-endoscopy in Chronic Obstructive Pulmonary Disease (COPD) and Lung Transplant Recipients
|
N/A | |
| Not yet recruiting |
NCT01162148 -
Pulmonary Rehabilitation and Inspiratory Muscle Training (IMT) for Patients Following Lung Transplantation
|
N/A | |
| Active, not recruiting |
NCT00980967 -
Predictive Factors for Chronic Rejection in Lung Transplant Recipients: COLT Study
|
N/A | |
| Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
| Recruiting |
NCT00163696 -
Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease
|
N/A | |
| Completed |
NCT00177684 -
Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)
|
Phase 3 | |
| Completed |
NCT00163891 -
Comparison of Two Chest Physiotherapy Protocols in Lung Transplant Recipients
|
N/A | |
| Completed |
NCT03668483 -
Relation Between Muscle Strength With Exercise Capacity and Dyspnea in LTx
|
N/A | |
| Not yet recruiting |
NCT02855372 -
Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT)
|
N/A | |
| Completed |
NCT01211509 -
Montelukast in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Completed |
NCT01212406 -
Vitamin D in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
| Not yet recruiting |
NCT00808600 -
Empowerment of Lung and Heart-lung Transplant Patients
|
N/A | |
| Completed |
NCT00553397 -
Live Lung Donor Retrospective Study
|
N/A | |
| Completed |
NCT00402805 -
Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy
|
Phase 4 | |
| Terminated |
NCT00235651 -
Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients
|
Phase 3 | |
| Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
| Active, not recruiting |
NCT02936505 -
Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.
|
N/A |